FCGR3A and Hodgkins lymphoma: For instance, the CD16 bispecific antibody AFM13, targeting CD30, achieved an objective remission rate of nearly 100% when combined with NK cells derived from umbilical cord blood for the treatment of patients with relapsed/refractory Hodgkin lymphoma (RR-HL) (126).